Cardiokinase™ (Strain N -Nattokinase
"Cardiokinase has literally created a new standard for the nattokinase market. The bar is raised so high that such an achievement can only be accomplished by the researcher who discovered the original nattokinase, Dr. Sumi. It should be appropriate that Dr. Sumi himself did all the scientific development of this new substance in Cardiokinase and the only nattokinase on the market that has his stamp of approval."
Chad Larson, DC, CCN, ND (candidate)
Director of Nutrition, Pure Prescriptions, Inc.
Cardiokinase features nattokinase "Strain N", an enzyme that is extracted from the traditional Japanese soy food called "natto." Nattokinase was first discovered by Dr. Hiroyuki Sumi, PhD. Natto has been used traditionally to support cardiovascular health. Modern research has revealed that nattokinase works by breaking down fibrin, a protein involved in clotting of the blood.*
Cardiokinase Technical Data
Hypertension is among the many illnesses associated with an unhealthy lifestyle. When left untreated, hypertension can contribute to the formation of atherosclerosis. Hypertension and atherosclerosis are the key risk factors to cerebrovascular and cardiac disease.
In 1980, Dr. Hioryuki Sumi discovered that "natto," a traditional fermented food in Japan, possesses previously unidentified thrombolytic activity. He referred to the isolated enzyme as nattokinase. Although nattokinase is not new to the marketplace, there is a new strain that exhibits some exceptional improvements over the original. It should be appropriate then that Dr. Sumi himself set the new bar with the scientific development on this new substance. We will highlight some of the key advancements that clearly delineate it from any other nattokinase on the market. This new product is called Cardiokinase (CK).
1. CK utilizes a new standardization for fibrinolytic activity which is more sensitive and specific to nattokinase activity. Originally, the Fibrin Unit (FU) method was created for the sake of convenience. Because fibrin, which is insoluble in water, is used as the substrate, accurate measurement of the enzyme reaction is not possible through this method. Therefore, to accurately measure the potency of CK, International Units (IU) are required to quantify the results of the enzyme activity.
2. Cardiokinase incorporates a new strain (“strain N”) of Bacilius Substilisin that produces higher activity than other strains. In particular, the cultured solution of the CK (N strain), displayed activity that was 17.9 times greater that of the control. Furthermore, fibrinolytic activity was also observed in the bacteria itself, and the activity on the N strain elevated to a level that was 70 times as much as the control. The therapeutic benefit of this type of activity on human cells is the promotion of the release of tissue-plasminogen activator (t-PA). t-PA is a protein involved in the breakdown of blood clots – it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
3. In addition to t-PA, CK has demonstrated a new mechanism of action involving fibrinolytic pharmacokinetics. This new strain of nattokinase has shown for the first time that is has a higher kinin-producing capacity than plasma kininogen. The physiological activities of kinin (and its products like bradykinin) include lowering blood pressure, promotion of capillary permeability, local vasodilation, smooth muscle contraction, promotion of lymph flow, and inflammatory modulation. This kinin-producing activity is involved in the circulatory systems of all internal organs.
Cardiokinase's hypotensive and circulation-improving effects have the potential to replace other more invasive and ADR-promoting medications in the conventional and alternative marketplace.
4. Another novel characteristic of CK is its anti-viscogenic effect. No other natural substance has demonstrated the ability to quantitatively lower blood viscosity as CK has. The applications of this attribute alone make CK one of the most useful therapies in even the most serious cardiovascular conditions.
5. Lastly, unlike other commercial sources of nattokinase, Cardiokinase incorporates a non-corn source of maltodextrin, making it the most hypoallergenic source of nattokinase on the market.
Q: I noticed Cardiokinase has 25 IU per softgel-What is an I.U.?
A: -I.U. stands for International Unit.
Q:I notice that a unit of measurement for other nattokinase uses FU. Translated, how many FU's is 25 I.U.?
A: -FU, or Fibrinolytic Unit is an old standard of measurement and is not endorsed by Dr. Sumi. However, tests have been performed comparing 100 mg (25 IU) of Cardiokinase to older forms of Nattokinase: 25 IU = 2500 FU. Typical nattokinase has only 2000 FU/100 mg, therefore making Cardiokinase a much more effective material